The U.S. FDA has granted accelerated approval to Novartis AG’s Fabhalta (iptacopan) for reducing proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) at risk of rapid disease progression. The approval strengthens the company’s renal disease presence as it puts two other IgAN treatments through clinical trials.
Dren Bio Inc. has entered into a strategic collaboration with Novartis Pharma AG which will focus on the discovery and development of therapeutic bispecific antibodies for cancer leveraging Dren Bio’s proprietary Targeted Myeloid Engager and Phagocytosis Platform.
A new collaboration with Dren Bio Inc. means Novartis Pharma AG has negotiated two of the biggest deals of 2024, with its parent company Novartis AG signing a third. Privately held Dren is getting $150 million up front and the chance to ultimately bring in $2.85 billion. The $150 million up-front payment includes a $25 million equity investment.
There is no doubt that artificial intelligence, automation and robotics are transforming today’s laboratories. At the forefront of these changes is Automata Technologies Ltd., which has developed the Linq platform to digitally and robotically connect all the components of a modern life sciences lab to create fully automated end-to-end workflows.
The U.S. Department of Health and Human Services (HHS) and the FDA already are getting a glimpse of the post-Chevron world and how the Supreme Court’s June 28 unwinding of the 40-year-old Chevron deference could rein in agency policies that defy Congress’ expressed intent.
Top-line phase III data from G1 Therapeutics Inc.’s pivotal Preserve 2 study of Cosela (trilaciclib) in treating metastatic triple-negative breast cancer missed its primary endpoint of overall survival, submerging the stock on June 24.
Marea Therapeutics came out of stealth mode on June 18, after raising a combined $190 million through its series A and B financings. The series A round was led by Third Rock Ventures, and the series B round was led by Sofinnova Investments and co-led by Forbion, Perceptive Xontogeny Venture Fund and Venbio.
The ongoing European Association for the Study of the Liver 2024 congress in Milan opened yesterday with several presentations on cell plasticity and its role in liver function and regeneration in chronic liver disease situations.
South Korea’s Celltrion Inc. secured May 22 the European Commission’s go-ahead for Omlyclo (CT-P39) to be the first biosimilar to Genentech Inc./Novartis AG’s Xolair (omalizumab) in Europe for three of its major indications.
South Korea’s Celltrion Inc. secured May 22 the European Commission’s go-ahead for Omlyclo (CT-P39) to be the first biosimilar to Genentech Inc./Novartis AG’s Xolair (omalizumab) in Europe for three of its major indications.
